FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers

Share this content:
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers

FRIDAY, Dec. 1, 2017 (HealthDay News) -- Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.

The maker of a biosimilar must demonstrate that the new product is highly similar to an already approved medication, and that it has no clinically significant difference in terms of its potency, safety, and purity, the FDA said.

Ogivri is approved to treat breast and gastric or gastroesophageal junction adenocarcinoma cancers attributed to human epidermal growth factor receptor 2. The FDA said its maker, Mylan, provided sufficient evidence that the drug is biosimilar to the Genentech drug Herceptin, which was approved by the agency in 1998.

Expected side effects for Ogivri include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough, and rash, the FDA said. Like Herceptin, Ogivri's label will include a boxed warning about an increased risk of heart disease, serious allergic-like reactions, lung damage, and harm to a developing fetus, the agency said.

Mylan is based in Canonsburg, Penn.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »